Preliminary Results for the Year Ended 31 December 2025

Why It Matters

Advancing three clinical‑stage assets while bolstering cash reserves positions Biodexa to capture a niche in gastrointestinal oncology, but sustained financing will be critical to reach commercialization.

Key Takeaways

• Phase 3 eRapa trial enrolls first US and EU patients.
• MTX240 in‑licensed from Otsuka, Phase 1b/2a planned.
• $10 million equity raise extends runway to Q3 2026.
• R&D spend cut 27% to $5 million, cash $11 million.
• Loss of $8 million despite non‑dilutive grant support.

Pulse Analysis

Biodexa’s strategic pivot toward gastrointestinal oncology reflects a broader industry trend of targeting high‑unmet‑need cancers with precision‑focused therapeutics. eRapa’s oral rapamycin formulation leverages mTOR inhibition, a pathway increasingly validated in hereditary polyposis syndromes, and its Fast Track and Orphan designations could accelerate regulatory timelines. By enrolling patients across the United States and Europe, the Serenta trial not only expands the drug’s geographic footprint but also builds a robust data set that may attract late‑stage partners seeking to co‑commercialize a differentiated oral therapy.

Financing remains a linchpin for early‑stage biotechs, and Biodexa’s recent capital actions illustrate a balanced approach. The $10 million equity raise, combined with an $8.9 million draw on a $35 million revolving facility, lifts cash on hand to roughly $11 million, enough to fund near‑term trial milestones. Crucially, the $20 million grant from CPRIT underscores the value of non‑dilutive funding in de‑risking development costs, while the $3 million additional CPRIT award demonstrates continued confidence from public‑sector investors. However, the company’s $8 million loss signals that cash burn will persist until product milestones translate into partnership deals or market entry.

From a market perspective, the gastrointestinal stromal tumor (GIST) space, valued at about $1.3 billion globally, is ripe for disruption as resistance to existing tyrosine‑kinase inhibitors rises. MTX240’s novel molecular‑glue mechanism could address this gap, positioning Biodexa as a potential acquisition target or licensing partner. Meanwhile, eRapa’s orphan status may command premium pricing if approved, offering upside for shareholders. Investors should monitor enrollment velocity, interim readouts, and any partnership announcements, as these will dictate whether Biodexa can transition from a cash‑flow‑negative R&D entity to a value‑creating asset in the competitive oncology landscape.